scholarly journals Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice

2021 ◽  
Vol 26 (10) ◽  
pp. 4699
Author(s):  
S. R. Gilyarevsky
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Randomized Clinical Trials ◽  
Decompensated Heart Failure ◽  
Mechanisms Of Action ◽  
Heart Failure Therapy ◽  
Reduced Ejection Fraction ◽  
Therapy Effectiveness ◽  
Real Practice ◽  
Epidemiological Significance

This review considers the clinical and epidemiological significance of hospitalizations for decompensated heart failure, as well as using it as an indicator of therapy effectiveness. The data on the frequency of using medications that reduce the hospitalization risk in randomized clinical trials and in real practice are presented. The reasons for inadequate prescription of drugs for the treatment of heart failure with reduced ejection fraction and their use in insufficient doses, which include therapeutic inertness and physiological limitations, as well as the need to introduce drugs with alternative mechanisms of action into clinical practice, are iscussed.

scholarly journals Serial echocardiographical assessment for urgent control of rapid atrial fibrillation in acute heart failure

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
N Iwahashi ◽  
J Kirigaya ◽  
M Horii ◽  
Y Hanajima ◽  
T Abe ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Right Heart Catheterization ◽  
Heart Catheterization ◽  
Reduced Ejection Fraction ◽  
Initial Hospitalization

Abstract Objectives Doppler echocardiography is a well-recognized technique for noninvasive evaluation; however, little is known about its efficacy in patients with rapid atrial fibrillation (AF) accompanied by acute decompensated heart failure (ADHF). The aim of this study was to explore the usefulness of serial echocardiographical assessment for rapid AF patients with ADHF. Patients A total of 110 ADHF patients with reduced ejection fraction (HFrEF) and rapid AF who were admitted to the CCU unit and received landiolol treatmentto decrease the heart rate (HR) to <110 bpm and change HR (ΔHR) of >20% within 24 hours were enrolled. Interventions Immediately after admission, the patients (n=110) received landiolol, and its dose was increased to the maximum; then, we repeatedly performed echocardiography. Among them, 39 patients were monitored using invasive right heart catheterization (RHC) simultaneously with echocardiography. Measurements and main results There were significant relationships between Doppler and RHC parameters through the landiolol treatment (Figure, baseline–max HR treatment). We observed for the major adverse events (MAE) during initial hospitalization, which included cardiac death, HF prolongation (required intravenous treatment at 30 days), and worsening renal function (WRF). MAE occurred in 44 patients, and logistic regression analyses showed that the mean left atrial pressure (mLAP)-Doppler (odds ratio = 1.132, 95% confidence interval [CI]: 1.05–1.23, p=0.0004) and stroke volume (SV)-Doppler (odds ratio = 0.93, 95% confidence interval [CI]: 0.89–0.97, p=0.001) at 24 hours were the significant predictors for MAE, and multivariate analysis showed that mLAP-Doppler was the strongest predictor (odds ratio = 1.16, 95% CI: 0.107–1.27, p=0.0005) (Table). Conclusions During the control of the rapid AF in HFrEF patients withADHF, echocardiography was useful to assess their hemodynamic condition, even at bedside. Doppler for rapid AF of ADHF Funding Acknowledgement Type of funding source: None

scholarly journals SERUM ASYMMETRIC DIMETHYLARGININE AND 1-YEAR MORTALITY IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE AND REDUCED EJECTION FRACTION

2011 ◽  
Vol 57 (14) ◽  
pp. E375
Author(s):  
Michael Zairis ◽  
Nikolaos Patsourakos ◽  
Evdokia Adamopoulou ◽  
Anastassios Theodosis Georgilas ◽  
Kyriakos Argyrakis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Asymmetric Dimethylarginine ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Reduced Ejection Fraction

scholarly journals Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure

2020 ◽  
Vol 16 (3) ◽  
pp. 202-211
Author(s):  
Yaniel Castro-Torres ◽  
Richard E. Katholi
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Mineralocorticoid Receptor ◽  
Sodium Current ◽  
Mineralocorticoid Receptor Antagonists ◽  
Neuregulin 1 ◽  
Reduced Ejection Fraction ◽  
Vasoactive Peptides ◽  
Patients With Heart Failure ◽  
Erbb Signaling

: Heart Failure (HF) represents a leading cause of morbidity and mortality worldwide. Despite the recent advances in the treatment of this condition, patients´ prognosis remains unfavorable in most cases. Sacubitril/valsartan and ivabradine have been recently approved to improve clinical outcomes in patients with HF with reduced ejection fraction. Drugs under investigation for treating patients with HF encompass many novel mechanisms including vasoactive peptides, blocking inflammatory- mediators, natriuretic peptides, selective non-steroidal mineralocorticoid-receptor antagonists, myocardial β3 adrenoreceptor agonists, inhibiting the cytochrome C/cardiolipin peroxidase complex, neuregulin-1/ErbB signaling and inhibiting late inward sodium current. The aim of this manuscript is to review the main drugs under investigation for the treatment of patients with HF and give perspectives for their implementation into clinical practice.

scholarly journals Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry

2017 ◽  
Vol 80 (12) ◽  
pp. 750-757 ◽  
Author(s):  
Hung-Yu Chang ◽  
Chun-Chieh Wang ◽  
Jeng Wei ◽  
Chong-Yi Chang ◽  
Yi-Cheng Chuang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction

scholarly journals Oral Metolazone Versus Intravenous Chlorothiazide as an Adjunct to Loop Diuretics for Diuresis in Acute Decompensated Heart Failure With Reduced Ejection Fraction

2018 ◽  
Vol 54 (6) ◽  
pp. 351-357 ◽  
Author(s):  
Brian C. Bohn ◽  
Rim M. Hadgu ◽  
Hannah E. Pope ◽  
Jerrica E. Shuster
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Oral Formulation ◽  
Loop Diuretics ◽  
Reduced Ejection Fraction ◽  
Significant Difference ◽  
Patients With Heart Failure ◽  
Total Urine

Background: Thiazide diuretics are often utilized to overcome loop diuretic resistance when treating acute decompensated heart failure (ADHF). In addition to a large cost advantage, several pharmacokinetic advantages exist when administering oral metolazone (MTZ) compared with intravenous (IV) chlorothiazide (CTZ), yet many providers are reluctant to utilize an oral formulation to treat ADHF. The purpose of this study was to compare the increase in 24-hour total urine output (UOP) after adding MTZ or CTZ to IV loop diuretics (LD) in patients with heart failure with reduced ejection fraction (HFrEF). Methods and Results: From September 2013 to August 2016, 1002 patients admitted for ADHF received either MTZ or CTZ in addition to LD. Patients were excluded for heart failure with preserved ejection fraction (HFpEF) (n = 469), <24-hour LD or UOP data prior to drug initiation (n = 129), or low dose MTZ/CTZ (n = 91). A total of 168 patients were included with 64% receiving CTZ. No significant difference was observed between the increase in 24-hour total UOP after MTZ or CTZ initiation (1458 [514, 2401] mL vs 1820 [890, 2750] mL, P = .251). Conclusions: Both MTZ and CTZ similarly increased UOP when utilized as an adjunct to IV LD. These results suggest that while thiazide agents can substantially increase UOP in ADHF patients with HFrEF, MTZ and CTZ have comparable effects.

Sign in / Sign up

Export Citation Format

Share Document